Candel Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	13.89	14.06	10.67	5.18	2.56
Research & Development	24.51	20.79	15.18	8.75	6.61
Operating Expenses	38.39	34.85	25.85	13.94	9.16
Operating Income	-38.39	-34.85	-25.85	-13.94	-9.16
Interest Expense / Income	2.6	1.71	0.05	-0.11	-1.07
Other Expense / Income	-3.05	-17.76	10.22	3.86	0.15
Pretax Income	-37.94	-18.79	-36.12	-17.68	-8.24
Net Income	-37.94	-18.79	-36.12	-17.68	-8.24
Shares Outstanding (Basic)	29	29	19	12	12
Shares Outstanding (Diluted)	29	29	19	12	12
Shares Change	0.39%	52.72%	62.49%	0.71%	-
EPS (Basic)	-1.31	-0.65	-1.91	-1.52	-0.71
EPS (Diluted)	-1.31	-0.65	-1.91	-1.52	-0.71
Free Cash Flow	-34.52	-32.72	-24.05	-10.55	-5.34
Free Cash Flow Per Share	-1.19	-1.14	-1.27	-0.91	-0.46
EBITDA	-34.14	-16.1	-35.84	-17.7	-9.27
Depreciation & Amortization	1.2	0.99	0.23	0.09	0.04
EBIT	-35.34	-17.09	-36.07	-17.79	-9.31

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).